Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

1(20%)

Results Posted

0%(0 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Terminated(1)

Detailed Status

Completed3

Active, not recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

completed360%

active_not_recruiting120%

terminated120%

Recent Activity

1 active trials

Showing 5 of 5

active_not_recruitingphase_1

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

NCT03252938

terminatedphase_1

Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen

NCT00354263

Clinical Trials (5)

Showing 5 of 5 trials

NCT03252938Phase 1

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Active Not Recruiting

NCT00365937Phase 1

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Terminated

NCT00349934Phase 1

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

Completed

NCT00351949Phase 1

IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)

Completed

NCT00354263Phase 1

Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5